S
Steven A. Pergam
Researcher at Fred Hutchinson Cancer Research Center
Publications - 152
Citations - 5450
Steven A. Pergam is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 27, co-authored 133 publications receiving 4266 citations. Previous affiliations of Steven A. Pergam include University of Washington & University of New Mexico.
Papers
More filters
Journal ArticleDOI
Pregnancy Complications Associated With Hepatitis C: Data From 2003-2005 Washington State Birth Cohort
Journal ArticleDOI
Predictive Value of 3 Clinical Criteria for Sepsis (Quick Sequential Organ Failure Assessment, Systemic Inflammatory Response Syndrome, and National Early Warning Score) With Respect to Short-term Mortality in Allogeneic Hematopoietic Cell Transplant Recipients With Suspected Infections.
Margaret Lind,Amanda I. Phipps,Amanda I. Phipps,Stephen J. Mooney,Stephen J. Mooney,Catherine Liu,Alison E. Fohner,Kevin R. Patel,Masumi Ueda,Steven A. Pergam,Steven A. Pergam +10 more
TL;DR: The data suggest that population-specific sepsis criteria are needed for immunocompromised patients, and News outperformed qSOFA and SIRS, but all three criteria had low to moderate predictive accuracy and the magnitude of the known predictive limitations were at least as large as in general populations.
Journal ArticleDOI
Evaluation of oral beclomethasone dipropionate for prevention of acute graft-versus-host disease.
Paul J. Martin,Paul J. Martin,Terry Furlong,Scott D. Rowley,Steven A. Pergam,Steven A. Pergam,Michele E. Lloid,Mark M. Schubert,Mark M. Schubert,Kevin J. Horgan,Barry E. Storer,Barry E. Storer +11 more
TL;DR: Results of a double-blind, randomized placebo-controlled phase II study designed to test the hypothesis that acute graft-versus-host disease could be prevented by administration of oral BDP showed lower severity of mucositis strongly correlated with higher adherence to the schedule of study drug administration.
Journal ArticleDOI
Clinically significant drug interaction: letermovir and voriconazole.
Arianne Duong,Arianne Duong,Ania Sweet,Ania Sweet,Rupali Jain,Rupali Jain,Joshua A. Hill,Steven A. Pergam,Michael Boeckh,Catherine Liu +9 more
Journal ArticleDOI
Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients.
Joshua A. Hill,Joshua A. Hill,Danniel Zamora,Hu Xie,Laurel A Thur,Colleen Delaney,Colleen Delaney,Ann Dahlberg,Ann Dahlberg,Steven A. Pergam,Steven A. Pergam,Wendy M. Leisenring,Michael Boeckh,Michael Boeckh,Filippo Milano,Filippo Milano +15 more
TL;DR: In this paper, the cumulative incidence of CS-CMVi and CMV detection in 21 CMV-seropositive CBT recipients receiving letermovir prophylaxis with a historical cohort of 40 CBTs receiving high-dose valacyclovir pre-proposition.